ESMO HIGHLIGHTS 2024 – GU ROUNDTABLE DISCUSSION: Renal Cell Carcinoma
OR
Chapter selection available inside video player. Click here for outline.
00:10
LBA73 Tivozanib–Nivolumab vs Tivozanib Monotherapy in Patients with Renal Cell Carcinoma (RCC) Following 1 or 2 Prior Therapies including an Immune Checkpoint Inhibitor (ICI) – Results of the Phase III TiNivo-2 Study
08:02
LBA75 Prospective randomised phase-II trial of Ipilimumab/Nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial
Chair
Dr. Christian Kollmannsberger
Panelists
Dr. Maria Jiang
Dr. Sebastian Hotte
